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Abstract: BACKGROUND Given the need for early detection of organ involvement in systemic sclerosis,
we evaluated Tc-rhAnnexin V-128 for the detection of early stages of interstitial lung disease (ILD) in
respective animal models using single photon emission computed tomography (SPECT/CT). METHODS
In bleomycin (BLM)-challenged mice, fos-related antigen 2 (Fra-2) transgenic (tg) mice and respective
controls, lung injury was evaluated by analysis of hematoxylin and eosin (HE) and Sirius red staining,
with semi-quantification of fibrosis by the Ashcroft score. Apoptotic cells were identified by TUNEL
assay, cleaved caspase 3 staining and double staining with specific cell markers. To detect early stages of
lung remodeling by visualization of apoptosis, mice were injected intravenously with Tc-rhAnnexin V-128
and imaged by small animal SPECT/CT. For confirmation, biodistribution and ex vivo autoradiography
studies were performed. RESULTS In BLM-induced lung fibrosis, inflammatory infiltrates occurred as
early as day 3 with peak at day 7, whereas pulmonary fibrosis developed from day 7 and was most
pronounced at day 21. In accordance, the number of apoptotic cells was highest at day 3 compared
with saline controls and then decreased over time. Epithelial cells (E-cadherin+) and inflammatory cells
(CD45+) were the primary cells undergoing apoptosis in the earliest remodeling stages of experimental
ILD. This was also true in the pathophysiologically different Fra-2 tg mice, where apoptosis of CD45+
cells occurred in the inflammatory stage. In accordance with the findings on tissue level, at day 3 in
the BLM and at week 16 in the Fra-2 tg model, biodistribution and/or ex vivo autoradiography showed
increased pulmonary uptake of Tc-rhAnnexin V-128 compared with controls. However, accumulation of
the radiotracer and thus the signal intensity in lungs was too low to allow the differentiation of healthy and
injured lungs in vivo. CONCLUSION At the tissue level, Tc-rhAnnexin V-128 successfully demonstrated
early stages of ILD in two animal models by detection of apoptotic epithelial and/or inflammatory cells.
In vivo, however, we did not detect early lung injury. It remains to be investigated whether the same
applies to human ILD.
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Abstract
Background: Given the need for early detection of organ involvement in systemic sclerosis, we evaluated 99mTc-
rhAnnexin V-128 for the detection of early stages of interstitial lung disease (ILD) in respective animal models using
single photon emission computed tomography (SPECT/CT).
Methods: In bleomycin (BLM)-challenged mice, fos-related antigen 2 (Fra-2) transgenic (tg) mice and respective
controls, lung injury was evaluated by analysis of hematoxylin and eosin (HE) and Sirius red staining, with semi-
quantification of fibrosis by the Ashcroft score. Apoptotic cells were identified by TUNEL assay, cleaved caspase 3
staining and double staining with specific cell markers. To detect early stages of lung remodeling by visualization
of apoptosis, mice were injected intravenously with 99mTc-rhAnnexin V-128 and imaged by small animal SPECT/CT.
For confirmation, biodistribution and ex vivo autoradiography studies were performed.
Results: In BLM-induced lung fibrosis, inflammatory infiltrates occurred as early as day 3 with peak at day 7, whereas
pulmonary fibrosis developed from day 7 and was most pronounced at day 21. In accordance, the number of
apoptotic cells was highest at day 3 compared with saline controls and then decreased over time. Epithelial cells (E-
cadherin+) and inflammatory cells (CD45+) were the primary cells undergoing apoptosis in the earliest remodeling
stages of experimental ILD. This was also true in the pathophysiologically different Fra-2 tg mice, where apoptosis of
CD45+ cells occurred in the inflammatory stage. In accordance with the findings on tissue level, at day 3 in the BLM
and at week 16 in the Fra-2 tg model, biodistribution and/or ex vivo autoradiography showed increased pulmonary
uptake of 99mTc-rhAnnexin V-128 compared with controls. However, accumulation of the radiotracer and thus the
signal intensity in lungs was too low to allow the differentiation of healthy and injured lungs in vivo.
Conclusion: At the tissue level, 99mTc-rhAnnexin V-128 successfully demonstrated early stages of ILD in two animal
models by detection of apoptotic epithelial and/or inflammatory cells. In vivo, however, we did not detect early lung
injury. It remains to be investigated whether the same applies to human ILD.
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Background
Systemic sclerosis (SSc) is a devastating multisystem auto-
immune connective tissue disease with lung involvement
as the primary cause of death [1]. Interstitial lung disease
(ILD) occurs early in the disease course and affects 40–
70% of patients. Diagnostic tools such as pulmonary func-
tion tests (PFTs) or high-resolution computed tomography
(HRCT) often only detect irreversibly compromised lung
function and structure [2]. Consequently, there is a need
for the diagnosis of early, potentially reversible disease
stages. This need could be met by nuclear medicine appli-
cations such as single photon emission computed tomog-
raphy (SPECT/CT) and positron emission tomography
(PET). These highly sensitive and specific methodologies
allow the real-life visualization of pathophysiological
processes and have become valuable diagnostic tools in
oncology [3].
In SSc-ILD, pulmonary damage at its early stages is
characterized by apoptosis of epithelial cells (EPC) (up to
80%) [4] and inflammatory cells caused by, for example,
cigarette smoke, infections, environmental exposures or
micro-aspiration and/or locally increased oxidative and
endoplasmatic reticulum stress [5, 6]. Notably, in experi-
mental animal models of ILD, EPC damage [7] or the
delivery of apoptotic cells induce lung fibrosis [8, 9],
whereas blocking of apoptotic pathways prevents or atten-
uates the development [10–12]. Dying cells release cellular
contents such as adenosine triphosphate (ATP), uric acid
or high-mobility group protein B1 (HMGB-1), some of
which being recognized as danger-associated pathogens
(DAMPs) [13, 14]. In experimental ILD, signaling via dan-
ger receptors, including, for example, toll like receptors
(TLRs), initiates innate immune responses, thereby
promoting inflammation and fibrosis mainly through the
NFkB/inflammasome and IL-1 pathways [15]. In physio-
logic conditions, the DAMP-mediated influx of inflamma-
tory cells leads to the clearance of apoptotic debris and
the resolution of inflammation. In ILD, probably due to a
genetic predisposition, exaggerated DAMP signaling
occurs with a sustained pro-inflammatory response, part
of which is attributed to inefficient phagocytosis of
apoptotic cell debris (= efferocytosis) [16, 17]. Among the
phagocytosing cells, alternatively activated macrophages,
which are predominant in ILD [18, 19], are a major source
of transforming growth factor (TGF)β [20]. TGFβ induces
apoptosis of EPCs, thereby further enhancing the loss of
functional epithelium [21, 22]. Furthermore, TGFβ medi-
ates the differentiation of fibroblasts into myofibroblasts
rendering them resistant to apoptosis [23]. This results in
massively increased and perpetuated secretion of extracel-
lular matrix proteins. Although less well-investigated, it
has been suggested that adaptive immune responses might
also be involved in pathogenesis in ILD. Potential mecha-
nisms include cross-presentation of cellular DAMPs from
apoptotic epithelial or inflammatory cells by, for example,
dendritic cells, which could drive the activity of cytotoxic
T cells and thereby increase lung damage [24, 25]. In
addition, patient-derived data and data derived from
experimental ILD suggest a potential pathogenic
involvement of B cells [25–27] and a propensity towards a
T helper 2 (Th2) response [28]. Overall, in ILD, there is a
vicious cycle of dysregulated pro-apoptotic and
anti-apoptotic mechanisms involving different cell types,
which identifies apoptosis as an important initiator and
driver of lung fibrosis.
One of the first signals of cells undergoing apoptosis is
the rapid redistribution of phosphatidylserine (PS) onto the
cell surface, where annexin V binds with high affinity. PS
constitutes 10–15% of the phospholipids of the inner leaflet
of the plasma membrane [29]. Upon the onset of apoptosis,
closely following activation of caspase 3, translocation of PS
onto the cell surface results in a 100–1000-fold increase of
annexin V binding sites per cell [30]. Notably, annexin V
may also identify necrotic cells, since the disruption of the
membrane of necrotic cells may allow binding of annexin
V to PS at the inner leaflet [31]. In human pilot studies,
technetium-99 m (99mTc)-labeled annexin V has been used
to detect apoptosis and necrosis in the context of acute
myocardial infarction [32] and cardiac allograft rejection
[33]. Recent data from animal studies using models of (in-
fectious) endocarditis [34], atherosclerosis [35], myocarditis
[36] and rheumatoid arthritis [37] suggest a potential use
for the detection of early inflammatory disease stages.
In this study, we aimed to evaluate the potential of
99mTc-rhAnnexin V-128-based SPECT/CT to visualize
early stages of lung remodeling in two representative
mouse models of SSc-ILD, the model of bleomycin
(BLM)-induced lung fibrosis [38] and the Fos-related
antigen 2 (Fra-2) transgenic (tg) mouse model [39, 40].
Methods
Animal experiments
All animal experiments were approved by the cantonal
authorities and performed according to the Swiss animal
welfare guidelines. For all experiments, mice were randomly
assigned into the different study groups.
Model of BLM-induced lung fibrosis
The BLM-induced lung fibrosis model is a commonly
used animal model to study pulmonary inflammation and
fibrosis mimicking SSc-related ILD. BLM-induced ILD
develops in a time-dependent manner with inflammation
occurring by day 3 and peaking at day 7, while pulmonary
fibrosis develops later starting at day 7 and getting
maximal at day 21 after the BLM administration [41]. To
induce lung inflammation and fibrosis, female C57Bl6/J
mice age 7–8 weeks (Janvier Labs, Le Genest-Saint-Isle,
France) were intratracheally instilled with bleomycin
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sulfate (Baxter, Kantonsapotheke Zurich, Switzerland) at a
dosage of 4 U/kg of body weight. Control mice received
equivalent volumes of 0.9% saline solution. Mice were
sacrificed at days 3, 7, 14 and 21 after the instillation of
BLM (n = 3–4 receiving saline, n = 3–9 receiving BLM).
Fra-2 tg mouse model
Fra-2 tg mice express the transcription factor Fra-2 of the
activator protein-1 family under the control of the ubiqui-
tous major histocompatibility complex class I antigen
H2Kb promotor [39]. Fra-2 tg mice develop a multi-organ
phenotype, most importantly affecting the skin [40, 42]
and the lungs [43, 44]. Lung involvement of Fra-2 tg mice
is characterized by non-specific interstitial pneumonia
with mild interstitial fibrosis and severe proliferative
vascular remodeling resembling pulmonary hypertension
[43, 44]. Fra-2 tg mice were newly generated and provided
by Sanofi Genzyme (Framingham, MA, USA) and back-
crossed from a mixed genetic background (C57Bl6/J ×
CBA) to a pure C57Bl6/J background for more than 10
generations. In this study, 10, 14 and 16 week-old female
Fra-2 tg mice (n = 2–6) were used. Wild-type littermates
(n = 2–4) served as controls.
Histological analysis
For histological analysis, lungs were transcardially per-
fused with sterile phosphate-buffered saline solution (PBS)
to remove residual blood, fixed with 10% neutral-buffered
formalin and embedded into paraffin. Lung sections
(4 μm thick) were stained with hematoxylin and eosin
(HE) for the assessment of the overall lung architecture
and with Sirius red for the visualization of collagen depos-
ition according to standard protocols. For the analysis of
lung fibrosis, the semi-quantitative Ashcroft score was
applied as described previously [45]. In brief, successive
fields within the lung sections stained with Sirius red to
identify fibrotic areas (red) were observed under a micro-
scope at × 100 magnification and allotted a score from 0
(normal) to 8 (total fibrosis) according to the severity
(Table 1).
All histological specimens were evaluated by at least two
experienced examiners in a blinded fashion. The mean of
their individual scores was considered the final fibrotic
score. Staining was recorded automatically by the AxioS-
can.Z1 slidescanner (Carl Zeiss, Feldbach, Switzerland)
using a Plan-Apochromat 20×/0.8 M27 objective.
TUNEL assay
To detect apoptotic and necrotic cells in
paraffin-embedded lung sections, terminal deoxynucleotidyl
transferase (TdT)-mediated dUTP nick end labeling
(TUNEL) [46] was performed applying the ApopTag®
Fluorescein in Situ Apoptosis Detection Kit (Millipore,
USA) according to the manufacturer’s instructions. In brief,
after deparaffinization and rehydration, sections were
treated with proteinase K (20 μg/mL) for 15 min at room
temperature (RT). Subsequently, equilibration buffer was
applied for ~ 10 s, and then the specimens were incubated
for 1 h in working strength TdT enzyme solution at 37 °C.
Following incubation in stop/wash buffer for 10 min to
terminate the reaction, sections were incubated for 30 min
in working strength anti-digoxigenin conjugate at RT in the
dark to visualize the DNA fragments. Finally, slides were
counterstained with 0.5 μg/mL 4',6-diamidino-2-phenylin-
dole (DAPI) and mounted with fluorescence mounting
medium. Sections treated only with reaction buffer, but
without TdT enzyme were used as negative controls. To
quantify the numbers of apoptotic cells, pictures of six
randomly chosen high power fields (HPFs)/slide at × 200
magnification were taken by a blinded examiner using a
wide-field fluorescence microscope (Olympus BX53,
Volketswil, Switzerland). TUNEL+ nuclei were quantified
by automatic counting using Image J (NIH version1.47 t).
Immunohistochemical assessment
To visualize specifically apoptotic cells in
paraffin-embedded lung sections, we performed immu-
nohistochemical assessment for cleaved caspase 3. In
brief, after deparaffinization and rehydration, antigen
was retrieved using 10 mM sodium citrate buffer (pH =
6.0) at 95 °C for 15 min. After blocking endogenous
peroxidase activity with 3% hydrogen peroxide for
15 min at RT, sections were treated with 10% normal
goat serum (1 h, RT) to prevent unspecific antibody
binding and blocked for endogenous biotin using an
Avidin/Biotin blocking kit (Vector Laboratories, Burlin-
game, CA, USA). Afterwards, specimens were incubated
with monoclonal rabbit anti-mouse cleaved caspase 3
(1:1000, clone 5A1E, Cell Signaling, USA) overnight at
4 °C. Isotype-matched and concentration-matched IgG
Table 1 Fibrotic lung remodeling according to the Ashcroft
score [22]
Grade of fibrosis Histological changes
0 Normal lung
1 Minimal fibrous thickening of alveolar/bronchial walls
2 Intermediary stage between 1 and 3
3 Moderate thickening of walls without obvious
damage to the lung architecture
4 Intermediary stage between 3 and 5
5 Increased fibrosis with definite damage to lung
structure and formation of fibrous bands or small
fibrous masses
6 Intermediary stage between 5 and 7
7 Severe distortion of structure and large fibrous areas;
honeycombing lung is placed in this category
8 Total fibrous obliteration of the field
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was used as a negative control. Afterwards, a
biotin-labeled goat anti-rabbit secondary antibody
(Vector Laboratories) was applied (1:200, 30 min, RT).
This was followed by incubation with the Vectastain
ABC Elite HRP kit (Vector Laboratories, 30 min, RT).
Finally, staining was visualized using 3,3′-diaminobenzi-
dine (DAB, Vector Laboratories) and counterstained
with methyl green.
Staining was recorded automatically by the Zeiss
AxioScan.Z1. slidescanner using a Plan-Apochromat
20×/0.8 M27 objective. For cell counting, six randomly
selected, non-overlapping HPFs at × 400 magnification
were extracted per sample using the Zen 2.0 lite (blue
edition) software. All analyses were performed by two
blinded examiners.
Immunohistochemical double staining
To identify the cell types undergoing apoptosis, immuno-
histochemical double staining with cell-type-specific
markers were performed. For the double staining, cleaved
caspase 3-stained lung sections (without counterstain)
were subjected to an additional heat-mediated antigen
retrieval step using 10 mM sodium citrate buffer to avoid
unspecific staining when using primary antibodies origin-
ating from the same species. After repetition of the
aforementioned blocking steps, the following primary
antibodies were added: monoclonal mouse anti-mouse
alpha smooth muscle actin (αSMA, 1:750, clone 1A4,
Sigma, Switzerland), monoclonal rat anti-mouse CD45
(1:50, clone 30-F11, BD Pharmingen, San Jose, CA, USA),
polyclonal rabbit anti-mouse von Willebrand factor (vWF)
(1:100, abcam, Cambridge, UK), and monoclonal mouse
anti-mouse E-cadherin (1:400 clone M168, abcam).
Isotype-matched and concentration-matched IgGs were
used as negative controls. All primary antibodies were
incubated overnight at 4 °C except for αSMA with a 1 h
incubation time at RT. Next, a direct alkaline
phosphatase-labeled goat anti-mouse secondary antibody
(Dako, Baar, Switzerland), or biotin-labeled goat anti-rat,
anti-mouse, or anti-rabbit secondary antibodies (all from
Vector Laboratories) were applied on the sections
(30 min, RT). This was followed in the latter case by
incubation with the Vectastain ABC Elite HRP kit. Finally,
staining was developed using Vector Red (Vector
Laboratories) or HistoGreen (Histoprime; Linaris,
Wertheim-Bettingen, Germany).
Pictures were recorded at × 400 magnification using
the Olympus BX53 microscope in brightfield mode. For
semi-quantification of the number of apoptotic leuco-
cytes, epithelial cells, myofibroblasts or endothelial cells,
three randomly selected HPFs were taken per sample
and double positive cells were manually counted by two
blinded examiners.
Biodistribution of 99mTc-rhAnnexin V-128
After intravenous (i.v.) injection of ~ 10 MBq 99mTc-rhAn-
nexin V-128 (kindly provided by Advanced Accelerator
Applications, Novartis Company, Saint-Genis Pouilly,
France) ex vivo biodistribution studies were performed in
BLM-treated mice and saline treated controls at day 3 after
the BLM instillation (n = 3, each) to assess the radiotracer
uptake in the organs and tissues of interest. Mice were
killed using carbon dioxide 4 h post injection (p.i.) of the ra-
diotracer and blood was taken, and organs of interest were
harvested and weighed. Radioactivity counts were measured
in a γ-counter (Packard Cobra II Auto Gamma, Perkin
Elmer, Switzerland). The percentage of injected activity per
gram tissue (% IA/g) was calculated for each sample.
Ex vivo autoradiography
After i.v. injection of the radiotracer 99mTc-rhAnnexin
V-128 (~ 10 MBq) (1 h p.i. Fra-2 model, 4 h p.i. BLM
model), lungs were harvested and embedded in
Tissue-Tek O.C.T. compound, and snap frozen at opti-
mal cutting temperature. Fresh frozen sections 8-μm
thick were cut using a cryotom and were subsequently
exposed on a phosphoimager screen (super resolution
type SR, PerkinElmer, Waltham, USA) for 30 min. The
phosphoimager screen images were read using a Cyclo-
nePlus (PerkinElmer, Waltham, USA).
In vivo imaging using small animal SPECT/CT
BLM-treated, Fra-2 tg mice and respective controls were
scanned using a small animal SPECT/CT scanner (NanoS-
PECT/CT, Mediso, Budapest, Hungary) at 4 h after
injection of ~ 10 MBq 99mTc-rhAnnexin V-128 [36, 47].
Imaging were acquired using the Nucline software (version
1.02, Bioscan). SPECT/CT data were reconstructed
iteratively by HiSPECT software (version 1.4.3049, Scivis
GmbH, Göttingen, Germany) using 99mTc γ-energies of
140 keV ± 10%, and visualized with VivoQuant (version 3.0,
Invicro, Boston, USA).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
(version 7.02, GraphPad Software, La Jolla, CA USA).
Non-parametric and non-related data were expressed as
median ±min/max values and the Mann-Whitney U test
was applied. For parametric, non-related data, expressed
as mean ± standard deviation (SD), the unpaired t test
was performed. P values less than 0.05 were considered
statistically significant.
Results
Apoptosis is an early phenomenon in the development of
lung fibrosis in different murine ILD models
Upon BLM challenge, lung remodeling occurred over
time with influx of mononuclear cells (days 3–7), loss of
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alveoli and thickening of the interstitium (days 7–21) as
assessed by HE staining (Fig. 1a). Fibrosis, i.e. the depos-
ition of extracellular matrix proteins as visualized by
Sirius Red staining (Fig. 1b) followed the inflammatory
stage (days 3–7) and was most pronounced at days 14
and 21, which was also reflected in the semi-quantitative
Ashcroft score (median(Q1,Q3) Ashcroft score at day 21
= 5(4.4, 6.3), p = 0.0286; Fig. 1e).To reliably detect apop-
tosis ex vivo, we performed TUNEL as well as caspase 3
stainings. There was a significant increase in TUNEL+
apoptotic cells as early as day 3 (median(Q1,Q3) = 6.34
(3.04,10.3) versus 0.75(0.42,0.96), p = 0.0095; Fig. 1c), which
was confirmed by staining for cleaved caspase 3 (Fig. 1d).
Semi-quantification showed a rapid decline of apoptotic
cells after day 7 (Fig. 1f, g), at which inflammation sub-
sided and fibrosis developed (Fig. 1a, /b). In accordance
with the pathophysiology of BLM-induced lung injury,
co-staining with specific cell markers identified the
apoptotic cells (cleaved caspase 3+) at days 3, 7, 14 and
21 as EPC (E-cadherin+; Fig. 2a) and leucocytes (CD45+;
Fig. 2c) (Additional file 1). At the given time points,
apoptosis of endothelial cells (vWF+; Fig. 2b) or
fibroblasts (αSMA+; Fig. 2d) did not occur or very rarely
occurred (Additional file 1). In summary, in the
investigated time period ranging from days 3 to 21,
apoptosis peaked at day 3. Then, it decreased rapidly
until day 7 and thereafter gradually until day 21,
although the numbers of apoptotic cells still remained
higher in the lungs of BLM-challenged mice compared
to controls (Fig. 1f, g).
In contrast to the model of BLM-induced lung fibrosis,
in which - following the route of administration - lung
injury started peribronchially and then spread to the
interstitium (Fig. 1), in Fra-2 tg mice, and pulmonary
vasculopathy was the initial pathophysiologic event start-
ing from week 10 as shown by HE staining (Fig. 3a).
Fig. 1 Time line of apoptosis in the model of bleomycin (BLM)-induced lung fibrosis. Hematoxylin and eosin (HE) staining (× 200) (a); Sirius Red
staining (collagen fibers identified by red staining; × 200) (b); TUNEL staining (× 200) (c); cleaved caspase 3 staining (× 200) (d), inlets show higher
magnifications (× 400), arrows highlight apoptotic cells; Ashcroft scores (e); semi-quantification of TUNEL+ cells (f) and semi-quantification of cleaved
caspase 3+ cells (g): n = 4 (saline) or n = 6–9 (BLM). Data in box plots are expressed as median (line), mean (+) and minimum and maximum values:
*p < 0.05, **p < 0.01, ***p < 0.001, Mann-Whitney U test. Scale bars 50 μm and 20 μm for inlets
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Later, perivascular inflammation (week 14), then intersti-
tial inflammation and to a lesser extent fibrosis (week
16), visualized by Sirius Red staining, occurred (Fig. 3b).
With more inflammation in the lungs of Fra-2 tg mice,
yet less fibrosis compared to BLM-challenged mice, the
semi-quantitative Ashcroft score at the peak of lung re-
modeling in Fra-2 tg mice (week 16) (median(Q1,Q3) = 4.3
(3.0, 4.6), p = 0.0095; Fig. 3e) was not as high as in the
respective period of the BLM lung model (day 14)
(median(Q1,Q3) = 5.3 (4.4, 5.8), p = 0.0048; Fig. 1e). In line
with the different pathophysiology, during the period of
observation (weeks 10–16) we observed a
time-dependent increase in pulmonary apoptotic cells
(TUNEL+, Fig. 3c; cleaved caspase 3+, Fig. 3d) starting
from week 10, continuing in week 14 and reaching its
peak at week 16 as assessed semi-quantitatively (Figs. 3f,
g). Compared with the BLM-challenged mice,
co-staining with the respective cell markers (Figs. 4a–d)
showed that CD45+ (Fig. 4c) leucocytes accounted for
the clear majority of apoptotic cells in the lungs
(Additional file 2).
Evaluation of the potential of 99mTc-rhAnnexin V-128 to
visualize apoptosis in different animal models of ILD
Following our observation at the tissue level that apop-
tosis could serve as a surrogate marker for early lung
Fig. 2 Identification of cell types undergoing apoptosis in the model of bleomycin (BLM)-induced lung fibrosis. Immunohistochemical co-staining
of cleaved caspase 3 (brown) with the epithelial cell marker E-cadherin (green) (a), with the endothelial cell marker von Willebrand factor (vWF)
(green) (b), with the pan-leucocyte marker CD45 (green) (c) and with the smooth muscle cell and myofibroblast marker alpha smooth muscle
actin (αSMA) (red) (d). Magnification is × 400. Inlets represent zoomed images. Representative pictures from three mice each are shown. Scale
bars 20 μm. Red arrows highlight double staining with the cell-type-specific markers, black arrows show single stained apoptotic cells
Schniering et al. Arthritis Research & Therapy  (2018) 20:183 Page 6 of 13
remodeling, we next evaluated the diagnostic potential
of the radiotracer 99mTc-rhAnnexin V-128 in both ani-
mal models of experimental ILD. In the BLM lung
model, at day 3, biodistribution analysis of 99mTc-rhAn-
nexin V-128 revealed a significant difference in the
radiotracer uptake (% IA/g) only in the lungs of
BLM-treated mice compared to controls (mean ± SD =
0.47 ± 0.09% IA/g versus 0.28 ± 0.05% IA/g; Fig. 5b), yet
not in other organs (Fig. 5a). These findings were
confirmed by ex vivo autoradiography of frozen lung
sections, where a higher accumulation of 99mTc-rhAn-
nexin V-128 (4 h p.i.) was observed in BLM-treated mice
compared with controls at day 3 post-instillation
(Fig. 5c). In the Fra-2 tg mouse model, 99mTc-rhAnnexin
V-128 clearly demonstrated apoptosis in the inflamed
lungs of Fra-2 tg mice using ex vivo autoradiography
(1 h p.i.; Fig. 6a).
Despite the encouraging ex vivo results, in vivo im-
aging of the earliest lung remodeling by visualization of
apoptosis with 99mTc-rhAnnexin V-128 SPECT/CT, in
the applied experimental conditions, was not successful
(Figs. 5d, 6b). No specific pulmonary accumulation of
the radiotracer was observed in either healthy or dis-
eased mice (4 h after injection of the radiotracer).
Fig. 3 Time line of apoptosis in the fos-related antigen 2 (Fra-2) transgenic (tg) mouse model. Hematoxylin and eosin (HE) staining (× 20) (a);
Sirius Red staining (collagen fibers identified by red staining; × 200) (b); TUNEL staining (× 200) (c); cleaved caspase 3 staining (× 200) (d), inlets
show higher magnifications (×400), arrows highlight apoptotic cells; Ashcroft scores (e), semi-quantification of TUNEL+ cells (f) and semi-quantification
of cleaved caspase 3+ cells (g): n = 3–4 (wild type) or n = 3–6 (Fra-2 tg). Data in box plots are median (line), mean (+) and minimum and maximum
values: *p <0.05, **p < 0.01, Mann-Whitney U test. Scale bars 50 μm and 20 μm for inlets
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Discussion
The impending approval of molecular targeted,
disease-specific therapies in SSc will provide unique treat-
ment opportunities [48]. However, to improve patient
outcome effectively, there is a need for earlier diagnosis of
organ involvement to create a real window of opportunity.
Sensitive nuclear imaging methodologies allowing the
visualization of pathophysiologic processes in real time
Fig. 4 Identification of cell types undergoing apoptosis in the fos-related antigen 2 (Fra-2) transgenic (tg) mouse model. Immunohistochemical
co-staining of cleaved caspase 3 (brown) with the epithelial cell marker E-cadherin (green) (a), with the endothelial cell marker von Willebrand
factor (vWF) (green) (b), with the pan-leucocyte marker CD45 (green) (c), and with the smooth muscle cell and myofibroblast marker alpha smooth
muscle actin (αSMA) (red) (d). Magnification is × 400. Inlets represent zoomed images. Representative pictures from three mice each are shown. Scale
bars 20 μm. Red arrows highlight double staining with the cell-type-specific markers, black arrows show single stained apoptotic cells
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Fig. 5 Imaging of apoptotic cells with 99mTc-rhAnnexin V-128 in bleomycin (BLM)-treated mice. a Biodistribution of 99mTc-rhAnnexin V-128 in relevant
organs of BLM-treated mice and saline controls. b Significantly greater lung uptake of the 99mTc-rhAnnexin V-128 radiotracer (4 h post injection (p.i.)) in
the lungs of BLM-treated mice at day 3 after the BLM instillation. c Ex vivo autoradiography of frozen lung sections derived from BLM-treated mice and
controls showing higher accumulation of 99mTc-rhAnnexin V-128 (4 h p.i.) in BLM-treated mice versus controls at day 3 post instillation. d In vivo single
photon emission computed tomography (SPECT/CT) of 99mTc-rhAnnexin V-128 (4 h p.i.) administrated to BLM-treated mice and saline controls at day
3 post instillation. Herein, the chest cavity including the heart and the lungs is shown. Data are expressed as mean ± SD, n = 3, *p < 0.05, unpaired
parametric Student’s t test. % IA/g, percentage of injected activity per gram tissue
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have become an integral part of the management of
patients with cancer [3]. Although routinely available, the
use of 18F-FDG-PET for the diagnosis and monitoring of
inflammatory diseases is limited. In inflammatory condi-
tions, increased signal intensity due to metabolic cell
activity may reflect both developing and resolving tissue
remodeling and is therefore not selective for early inflam-
matory stages [35, 49]. In (autoimmune) ILD, apoptosis
and inflammation represent potentially reversible stages of
tissue injury [5, 6].
This led us to investigate the diagnostic potential of
99mTc-rhAnnexin V-128 SPECT/CT in two pathophysio-
logically different models of SSc-ILD. In BLM-challenged
and Fra-2 tg mice, the radiotracer 99mTc-rhAnnexin V-128
successfully detected apoptosis in the inflammatory stages
as visualized by ex vivo autoradiography and confirmed by
biodistribution studies. These results correlated very well
with the identification of apoptotic EPC and leukocytes by
immunohistochemical fluorescence on tissue level. Most
published studies report good correlation between
TUNEL-positivity and signal intensity of 99mTc-rhAnnexin
V-128 imaging [36, 50–52]. However, although widely
accepted as a surrogate marker for apoptosis, TUNEL
staining relies on the detection of DNA strand breaks in
the nuclei of dead cells [46], which (a) occur after the up-
regulation of annexin V reflecting later stages of apoptosis
[53] and (b) are also characteristic of necrotic cells [54]. In
the pathogenesis of ILD, apoptosis rather than necrosis
plays a key role in the disease initiation and perpetuation
[6]. Thus, we additionally performed staining for cleaved
caspase 3, which is a marker for early to mediate processes
of apoptosis [53]. The fact that we obtained similar results
with both staining methodologies indicates that in our
models, the majority of cells were apoptotic. At the tissue
Fig. 6 Imaging of apoptotic cells with 99mTc-rhAnnexin V-128 in fos-related antigen 2 (Fra-2) transgenic (tg) mice. a Ex vivo autoradiography for
99mTc-rhAnnexin V-128 in the lungs of Fra-2 tg mice versus wild-type mice. Frozen lung sections derived from a Fra-2-tg mouse and a wild-type
mouse showed higher accumulation of 99mTc-rhAnnexin V-128 (1 h post injection (p.i.)) in lungs of transgenic mice. b In vivo single photon
emission computed tomography (SPECT/CT) of 99mTc-rhAnnexin V-128 (4 h p.i.) administrated to Fra-2 tg mice and wild-type littermates at age
19 weeks. Herein, the chest cavity including the heart and the lungs is shown
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level, 99mTc-rhAnnexin V-128 reliably detected apoptosis
as assessed by ex vivo autoradiography and biodistribution
studies, thereby clearly distinguishing diseased mice from
their respective controls. However, in both mouse models,
accumulation of the radiotracer and thus the signal inten-
sity in the lungs was too low to allow the diagnosis of ILD
in vivo in the tested experimental conditions. Although
the most likely explanation is the overall rather low num-
bers of apoptotic cells in our murine ILD models, we can-
not exclude that in our experimental setting the annexin
V dose and/or imaging time points were not ideal and
might need to be optimized in future trials. However, the
number of pulmonary apoptotic cells did not differ from
previously published murine ILD studies [39, 43, 55]. In
comparison, studies in which 99mTc-rhAnnexin V-128
SPECT/CT had been used to detect acute myocardial
infarction, allograft rejection or infectious/septic states in
vivo [32, 33, 36, 47] showed substantially higher
percentages or amounts of apoptotic cells per tissue area.
In general, nuclear imaging of lung pathology compared
with solid organs has inherent challenges, especially in
small animals with very rapid breathing rates.
Ventilation-triggered, i.e. gated, SPECT/CT imaging [56]
has great potential to increase both the quality and quan-
tity of SPECT/CT to such an extent that the detection of
apoptosis in lung diseases might become possible, at least
in disorders with more severe lung damage (e.g. acute
toxic or infectious lung injury). Additional improvement
might be achieved by excluding signal interference from
the unspecific high uptake of the radiotracer in neighbor-
ing metabolic organs (kidneys, liver). This might be real-
ized by, for example, focused imaging of the anatomical
region of interest, e.g. the chest instead of the whole body,
and/or by the adaptation of computational image recon-
struction techniques, e.g. by the analysis of defined regions
of interest [34–36]. Additionally, 99mTc-rhAnnexin
V-128 SPECT/CT has also shown some promise for
the monitoring of therapeutic responses and overall
disease outcome in, for example, infectious or cardiac
diseases [32, 47, 50].
Conclusions
In conclusion, 99mTc-rhAnnexin V-128 allowed successful
visualization of early stages of ILD in two animal models
by detection of apoptotic epithelial and/or inflammatory
cells in ex vivo samples. However, the transfer of
99mTc-rhAnnexin V-128 SPECT/CT into clinical applica-
tion to detect early, reversible stages of SSc-ILD remains
to be ascertained since in vivo imaging failed to detect
lung injury in our two mouse models. Nevertheless, the
development of innovative, targeted (nuclear) imaging
strategies is currently one of the most challenging pros-
pects in the field of autoimmune diseases to enable the
personalized management of these patients.
Additional files
Additional file 1: Semi-quantification of the number of leucocytes,
epithelial cells, myofibroblasts and endothelial cells undergoing apoptosis
in the model of BLM-induced lung fibrosis. Co-staining with specific cell
markers identified the apoptotic cells (cleaved caspase 3+) as EPC (E-cadherin)
and leucocytes (CD45+). Data are expressed as mean ± SD, n = 3 (each).
(TIF 422 kb)
Additional file 2: Semi-quantification of the number of leucocytes,
epithelial cells, myofibroblasts and endothelial cells undergoing apoptosis in
the Fra-2 tg mouse model. Co-staining with specific cell markers identified
the clear majority of apoptotic cells (cleaved caspase 3+) as leucocytes
(CD45+). Data are expressed as mean ± SD, n = 3 (each). (TIF 331 kb)
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